Literature DB >> 1016971

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.

K W Brunner, R W Sonntag, H J Ryssel, F Cavalli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1016971

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  12 in total

1.  [Successful therapy of chronic myelomonocytic leukemia with vp 16-213 (author's transl)].

Authors:  L Labedzki; H J Illiger
Journal:  Blut       Date:  1979-05

Review 2.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 3.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  The effect of dose on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 8.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 10.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.